Obsessive-compulsive disorders;Zwangsstörungen

Fortschritte der Neurologie Psychiatrie

Volumn 73, Issue 9, 2005, Pages 526-547

  Voderholzer, Ulrich ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG RESISTANCE; ELECTROCONVULSIVE THERAPY; GENETICS; HUMAN; MAXIMUM PERMISSIBLE DOSE; NEUROANATOMY; NEUROBIOLOGY; NEUROPSYCHOLOGY; NEUROSURGERY; OBSESSIVE COMPULSIVE DISORDER; PSYCHOTHERAPY; REVIEW; SEROTONINERGIC SYSTEM; TRANSCRANIAL MAGNETIC STIMULATION;

DIAGNOSIS, DIFFERENTIAL; DRUG RESISTANCE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; QUALITY OF LIFE;

EID: 25844469614     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830294     Document Type: Review

References (66)

1. Kessler R, McGonagle K, Zhao S et al. Lifetime and 12-month prevalence of DSM-II-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psych 1994; 51: 8-19
2. Bebbington PE. Epidemiology of obsessive-compulsive disorder. The British Journal of Psychiatry 1998; 173 (suppl 35): 2-6
3. Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder. Archives of General Psychiatry 1999; 56: 121-127
4. Hohagen F. Zwangsstörungen. In: Berger M (ed). Psychiatrie und Psychotherapie. München: Urban & Schwarzenberg, 1999
5. Broocks A, Hohagen F. Obsessive-Compulsive Disorder. In: Smelser NJ, Baltes PB (eds). The International Encyclopedia of the Social and Behavioral Sciences. Amsterdam: Elsevier, 2001
6. Berger M, Voderholzer U, Hohagen F. Obsessive-compulsive disorder: an underestimated disorder. In: Maj E, Sartorius N, Okasha A, Zohar J (Hrsg.) WPA Series Evidence and Experience in Psychiatry. 2000; 4: 297-299
7. Baer L, Jenike MA. Personality disorders in obsessive compulsive disorder. Psychiatr Clin North Am 1992; 15: 803-812
8. Pigott TA, L'Heureux F, Dubbert B, Bernstein S, Murphy DL. Obsessive compulsive disorder: comorbid conditions. J Clin Psychiatry 1994; 55 Suppl: 15-32
9. Thiel A, Broocks A, Ohlmeier M, Jacoby GE, Schussler G. Obsessive-compulsive disorder among patients with anorexia nervosa and bulimia nervosa. Am J Psychiatry 1995; 152: 72-75
10. Overbeek T, Schruers K, Vermetten E, Griez E. Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect. J Clin Psychiatry 2002; 63: 1106-1112
11. Regier DA, Boyd JH, Burke JD Jr et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1998; 45: 977-986
12. Poyurovsky et al. Obsessive-Compusive Disorder in Schizophrenia. Clinical Characteristics and Treatment. CNS Drugs 2004; 18: 989-1010
13. Kano Y, Ohta M, Nagai Y. Clinical characteristics of Tourette syndrome. Psychiatry Clin Neurosci 1998; 52: 51-57
14. Petter T, Richter MA, Sandor P. Clinical features distinguishing patients with Tourette's syndrome and obsessive-compulsive disorder from patients with obsessive-compulsive disorder without tics. J Clin Psychiatry 1998; 59: 456-459
15. Baer L, Jenike MA, Ricciardi JN et al. Standardized assessment of personality disorders in obsessive-compulsive disorder. Arch Gen Psychiatry 1990; 47: 826-830
16. Summerfeldt LJ, Huta V, Swinson RP. Personality and obsessive-compulsive disorder. In: Swinson RP, Antony MM, Rachman S, Richter MA. Obsessive-Compulsive Disorder. Theory, research, and treatment. New York, London: The Guilford Press, 1998: 79-119
17. Swinson RP, Antony MM, Rachman S, Richter MA. Obsessive-Compulsive Disorder. Theory, research, and treatment. New York: Guilford Press, 1998
18. Stengler-Wenzke K, Beck M, Holzinger A, Angermeyer MC. Stigmatisierungserfahrungen von Patienten mit Zwangserkrankungen. Fortschr Neurol Psychiat 2004; 72: 7-13
19. Baxter LR. Neuroimaging studies of obsessive compulsive disorder. Psychiatr Clin North Am 1992; 15: 871-884
20. Schwartz JM, Stoessel PW, Baxter LR, Martin KM, Phelps ME. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1996; 53: 109-113
21. Ebert D, Speck O, Konig A, Berger M, Hennig J, Hohagen F. 1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: evidence for neuronal loss in the cingulate gyrus and the right striatum. Psychiatry Res 1997; 74: 173-176
22. 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects. Am J Psychiatry 1998; 155: 1584-1591
23. Nicolson R, Swedo SE, Lenane M et al. An open trial of plasma exchange in childhood-onset obsessive-compulsive disorder without poststreptococcal exacerbations. J Am Acad Child Adolesc Psychiatry 2001; 39: 1313-1315
24. Murphy DL, Greenberg B, Altemus M, Benjamin J, Grady T, Pigott T. The Neuropharmacology and Neurobiology of Obsessive-compulsive Disorder. In: Westenberg HGM (ed). Advances in the Neurobiology of Anxiety Disorders. John Wiley & Sons, 1996a: 279-297
25. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999; 60: 101-106
26. Hoehn-Saric SR, Ninan P, Black DW et al. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry 2000; 57: 76-82
27. Stein DJ. Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry 2000; 47: 296-304
28. Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 1991; 145: 1521-1525
29. Benkelfat C, Murphy DL, Zohar J et al. Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action. Arch Gen Psychiatry 1989; 46: 23-28
30. Broocks A, Pigott TA, Hill JL et al. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. Psychiatry Res 1998c; 79: 11-20
31. Hollander E, DeCaria CM, Nitescu A et al. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 1992; 49: 21-28
32. Hollander E, Fay M, Cohen Bet al. Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. Am J Psychiatry 1988; 145: 1015-1017
33. Zohar J, Mueller EA, Insel TRet al. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry 1987; 44: 946-951
34. Hollander E, DeCaria C, Nitescu A. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to m-CPP in obsessive-compulsive disorder. Psychiatry Research 1992; 36: 1-17
35. Zohar J, Insel TR, Zohar Kadouch RCet al. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiatry 1988; 45: 167-172
36. Billet EA, Richter MA, Kennedy JL Genetics of obsessive-compulsive disorder. In: Swinson RP, Antony MM, Rachman S, Richter MA. Obsessive-Compulsive Disorder. Theory, research, and treatment. New York: Guilford Press, 1998: 181-206
37. Zohar J, Kennedy JL, Hollander E, Koran LM. Serotonin-1D Hypothesis of Obsessive-Compulsive Disorder: An update. J Clin Psychiatry 2004; 65: 18-21
38. Kuelz AK, Hohagen F, Voderholzer U. Neuropsychological performance in obsessive-compulsive disorder: a critical review. Biological Psychology 2004; 65: 185-236
39. Voderholzer U, Kuelz AK. Psychotherapy and pharmacotherapy of obsessive-compulsive disorder: New findings. 13th Congress of the Association of European Psychiatrists. 2005; (Abstract)
40. Berger M. Psychische Erkrankungen. Klinik und Therapie. 2. Aufl. München: Urban & Fischer, 2004
41. Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997; 65: 44-52
42. Hohagen F, Berger M. New perspectives in research and treatment of obsessive-compulsive disorder. Br J Psychiatry Suppl 1998; 35:1
43. Foa EB, Liebowitz MR, Kozak MJ et al. Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramin, and Their CombiNation in the Treatment of Obsessive-Compulsive Disorder. Am J Psychiatry 2005; 162: 151-161
44. Kordon A, Kahl KG, Broocks A et al. Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up. European Archives of Psychiatry & Clinical Neuroscience Feb 2005; 255: 48-50
45. Rufer M, Hand I, Braatz A et al. A prospective study of alexithymia in obsessive-compulsive patients treated with multimodal cognitive-behavioral therapy. Psychother Psychosom 2004; 73: 101-106
46. Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997; 65: 44-52
47. Kobak KA, GreistJH, Jefferson JW, Katzelnick DJ, Henk HJ. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology 1998; 136: 205-216
48. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 1995; 166: 424-443
49. Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 1995; 10: 11-18
50. Bergqvist PB, Bouchard C, Blier P. Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder. Biological Psychiatry 1999; 45: 164-174
51. Hohagen F, Winkelmann G, Rasche RH et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry 1998; Suppl 35: 71-78
52. Kordon A, Kahl KG, Broocks Aet al. Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up. European Archives of Psychiatry & Clinical Neuroscience Feb 2005; 255: 48-50
53. Geller DA, Biederman J, Stewart SE et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 2003; 160: 1919-1928
54. Hoehn-Saric SR, Ninan P, Black DW et al. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry 2000; 57: 76-82
55. Poyurovsky et al. Obsessive-Compusive Disorder in Schizophrenia. Clinical Characteristics and Treatment. CNS Drugs 2004; 18: 989-1010
56. The Clomipramine Collaborative Study Group (CCSG). Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48: 730-738
57. Tollefson GD, Rampey AH Jr, Potvin JH et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51: 559-567
58. Greist JH, Jefferson JW, Kobak KA et al. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995; 10: 57-65
59. Hollander E, Koran LM, Goodman WK et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 2003; 64: 640-647
60. Hollander E, Allen A, Steiner Met al. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 2003; 64: 113-121
61. Montgomery SA, Kasper S, Stein DJ et al. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001; 16: 75-86
62. Bystritsky A, Ackerman DL, Rosen RM et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 2004; 65: 565-568
63. Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004; 65: 1040-1048
64. McDougle CJ, Goodman WK, Leckman JF et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51: 302-308
65. Hollander E, Baldini-Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003; 6: 397-401
66. Shapira NA, Ward HE, Mandoki Met al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 2004; 55: 553-555